SCHEMBL2804144

SCHEMBL2804144

Cc1ccc(S(=O)(=O)NC2CCc3c(cnc4[nH]ncc34)C2)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TBXA2R P21731 5/20 0.42
HDAC8 Q9BY41 2/20 0.41
ALDH1A1 P00352 1/20 0.41
DRD2 P14416 2/20 0.38
ADRA1D P25100 1/20 0.38
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
MLNR O43193 1/20 0.37
DRD3 P35462 1/20 0.37
HTR6 P50406 1/20 0.37
GHSR Q92847 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
PKM P14618 1/20 0.37
TBXAS1 P24557 1/20 0.36
KIT P10721 2/20 0.36
PLAU P00749 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2803941 0.92 ALDH1A1 (0.49) TBXA2RHDAC8ALDH1A1LMNA
SCHEMBL2808103 0.91 HDAC8 (0.49) TBXA2RHDAC8ALDH1A1LMNATP53
SCHEMBL2804951 0.86 ALDH1A1 (0.44) TBXA2RALDH1A1TBXAS1KIT
SCHEMBL2809138 0.86 MEN1 (0.42) TBXA2RHDAC8ALDH1A1HTR6LMNA
SCHEMBL2807111 0.85 KMT2A (0.50) TBXA2RHDAC8ALDH1A1DRD2HTR6
SCHEMBL2804752 0.85 HDAC8 (0.50) TBXA2RHDAC8DRD2HTR6TBXAS1
SCHEMBL2805214 0.85 FBP1 (0.39) TBXA2RHDAC8ALDH1A1DRD2HTR6
SCHEMBL2804187 0.84 CYP3A4 (0.44) TBXA2RHDAC8ALDH1A1LMNATBXAS1
SCHEMBL2803517 0.84 RB1 (0.40) TBXA2RHDAC8ALDH1A1TBXAS1
SCHEMBL2808034 0.83 HDAC8 (0.52) HDAC8ALDH1A1DRD2ADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 TBXA2R 947/4885HDAC8 615/4885ALDH1A1 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.